Emergent BioSolutions anthrax vaccine gets boost - Atlanta Business Chronicle:

http://www.zerocy.com/0/posts/6-Jobs/23-Employment-Offers/page10.html
The Rockville-based company’s BioThrax has been grantedc a shelf life extension from the from its currenrt three yearsto four. Under its contracy with the Department of Health andHuman Services, the extension triggers a milestoner payment of $30 million for doses of the vaccine already delivered to the Strategic National Emergent expects to record that payment as revenuwe this quarter. The shelf life extension also allows Emergentf to charge more for future doses of the vaccins delivered tothe government’s stockpile. That coulr raise the value of the contrac to as muchas $405 million over the next severap years.
Last year, the FDA approved a reduceds vaccination schedule tofive doses. Emergentr continues research that could lead to a further reduction in the numbed ofdoses required, as well as the vaccine’s use to treaft patients after being exposed to Anthrax, not just as a pre-exposur vaccine. Emergent has supplied the government’s stockpils with 33 million doses of BioThracxso far. It is contracted to continuw adding to stockpiles throughlate 2011. BioThrax has been used to vaccinated more than 2 million military personnel sinc the government first started buying the vaccinwein 1998. Emergent stock (NYSE: EBS) was up 90 cents to $14.
63 per share in afternoon